



July 1, 2024

| | |
|-----------------|--|
| Company Name: | GNI Group Ltd. |
| Representative: | Director, Representative Executive Officer, President and CEO Ying Luo, PhD (Security Code: 2160, TSE Growth) |
| Contact Person: | Director, Executive Officer, and CFO Toshiya Kitagawa (TEL. 03-6214-3600) |

Notice Regarding Approval Granted for Avatrombopag Maleate Tablets (20mg)

GNI Group, Ltd. ("the Company", including its subsidiaries and affiliates, " the Group") is pleased to announce that the market application of "Avatrombopag Maleate Tablets (20mg)", the treatment for thrombocytopenia associated with chronic liver disease (CLD), which the Company's major subsidiary GYRE Pharmaceuticals has been developing in China, received approval from the National Medical Products Administration on June 25, 2024. This product will be the third product in the Company Group's sales lineup, following ETUARY[®] and Nintedanib. In addition, it is a generic drug for rare diseases. the Group will continue to innovate and expand its R&D pipeline to provide more options to patients with rare diseases in both new and generic drugs.

The impact of this matter on the Company Group's consolidated financial results for this fiscal year is minor.

Please refer to the following link for GYRE Pharmaceuticals 's press release.

[News - Gyre Pharmaceuticals \(bjcontinent.com\)](https://www.bjcontinent.com/news-gyre-pharmaceuticals)